| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| J0178 |
Injection, aflibercept, 1 mg |
10,669 |
5,903 |
$5.03M |
| J2778 |
Injection, ranibizumab, 0.1 mg |
5,363 |
2,863 |
$1.68M |
| 67028 |
Intravitreal injection of a pharmacologic agent |
23,469 |
14,002 |
$683K |
| Q5128 |
Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg |
756 |
471 |
$291K |
| 92250 |
|
8,395 |
6,128 |
$161K |
| 92134 |
|
21,876 |
14,168 |
$145K |
| 92235 |
|
3,765 |
2,730 |
$95K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
5,589 |
4,145 |
$90K |
| J9035 |
Injection, bevacizumab, 10 mg |
6,323 |
3,401 |
$87K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
1,688 |
1,287 |
$70K |
| 92012 |
Ophthalmological services: medical examination and evaluation, intermediate, established patient |
9,401 |
5,959 |
$67K |
| J3590 |
Unclassified biologics |
46 |
30 |
$62K |
| 92014 |
Ophthalmological services: medical examination and evaluation, comprehensive, established patient |
3,348 |
2,253 |
$47K |
| J3490 |
Unclassified drugs |
32 |
15 |
$39K |
| J0177 |
Injection, aflibercept hd, 1 mg |
23 |
14 |
$21K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
579 |
430 |
$11K |
| 67228 |
|
21 |
12 |
$2K |
| 5010F |
|
1,202 |
736 |
$0.00 |
| G8752 |
Most recent systolic blood pressure < 140 mmhg |
1,446 |
932 |
$0.00 |
| G9744 |
Patient not eligible due to active diagnosis of hypertension |
2,006 |
1,271 |
$0.00 |
| 2026F |
|
1,356 |
836 |
$0.00 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
3,244 |
2,071 |
$0.00 |
| 2024F |
|
1,358 |
838 |
$0.00 |
| G9974 |
Dilated macular exam performed, including documentation of the presence or absence of macular thickening or geographic atrophy or hemorrhage and the level of macular degeneration severity |
907 |
651 |
$0.00 |
| 2021F |
|
1,064 |
648 |
$0.00 |
| 2022F |
|
1,353 |
835 |
$0.00 |
| G8753 |
Most recent systolic blood pressure >= 140 mmhg |
22 |
12 |
$0.00 |
| 4177F |
|
1,602 |
1,007 |
$0.00 |
| 1036F |
|
2,694 |
1,724 |
$0.00 |
| G8754 |
Most recent diastolic blood pressure < 90 mmhg |
1,889 |
1,201 |
$0.00 |
| G9903 |
Patient screened for tobacco use and identified as a tobacco non-user |
1,647 |
1,173 |
$0.00 |
| 2019F |
|
673 |
351 |
$0.00 |
| G8952 |
Elevated or hypertensive blood pressure reading documented, indicated follow-up not documented, reason not given |
406 |
255 |
$0.00 |
| G8397 |
Dilated macular or fundus exam performed, including documentation of the presence or absence of macular edema and level of severity of retinopathy |
1,202 |
736 |
$0.00 |
| G9902 |
Patient screened for tobacco use and identified as a tobacco user |
12 |
12 |
$0.00 |